PB 6 of 2023

National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 1)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following determination.

Dated     30 January 2023    

NIKOLAI TSYGANOV

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1  Name

  This instrument is the National Health (Listed Drugs on F1 or F2) Amendment Determination 2023 (No. 1).

  This instrument may also be cited as PB 6 of 2023.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 85AB(1) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1        Schedule 1, after item dealing with Cannabidiol

omit:

Carbimazole

2        Schedule 1, after item dealing with Dolutegravir

omit:

Domperidone

3        Schedule 1, after item dealing with Evolocumab

omit:

Exenatide

4        Schedule 1, after item dealing with Larotrectinib

omit:

Ledipasvir with sofosbuvir

   Lenalidomide

5        Schedule 1, after item dealing with Onasemnogene abeparvovec

insert:

Opicapone

6        Schedule 1, after item dealing with Poly-l-lactic acid

omit:

Polyethylene Glycol 400 with Propylene Glycol

7        Schedule 1, after item dealing with Testosterone

omit:

Tetrabenazine

8        Schedule 2, after item dealing with Carbamazepine

insert:

Carbimazole

9        Schedule 2, after item dealing with Docetaxel

insert:

Domperidone

10   Schedule 2, after item dealing with Leflunomide 

insert:

Lenalidomide

11   Schedule 2, after item dealing with Plerixafor

insert:

Polyethylene glycol 400 with propylene glycol

12   Schedule 2, after item dealing with Teriparatide

insert:

Tetrabenazine